Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carica papaya flesh aqueous extract is a botanical preparation derived from the unripe fruit of the pawpaw tree (*Carica papaya*). It is primarily investigated for its potential role in the management of type 2 diabetes mellitus. The extract contains various phytochemicals that demonstrate inhibitory activity against key carbohydrate-metabolizing enzymes, specifically alpha-amylase and alpha-glucosidase, which helps in reducing postprandial glucose levels. Furthermore, it exhibits antioxidant properties by inhibiting sodium nitroprusside-induced lipid peroxidation in pancreatic tissues, potentially protecting beta cells from oxidative stress. While widely used in traditional folk medicine, its therapeutic profile is characterized by synergistic effects when combined with other parts of the fruit, such as the seeds and peel.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carica papaya flesh aqueous extract.